复方丹参联合低分子右旋糖酐预防造血干细胞移植后肝静脉闭塞病

 目的　观察复方丹参联合低分子右旋糖酐注射液预防造血干细胞移植（HSCT）后肝静脉闭塞病（HVOD）的临床效果。方法　在HSCT预处理时开始用复方丹参注射液20 ml，1次／d，静脉滴注，低分子右旋糖酐注射液250 ml，2次／d，静脉滴注，同时用保护肝细胞类药物。当血小板数降至30×109／L时停用复方丹参与低分子右旋糖酐，不再应用。结果　85次HSCT使用复方丹参联合低分子右旋糖酐预防HVOD均无HVOD发生，用复方丹参加低分子右旋糖酐时未发生出血。结论　复方丹参联合低分子右旋糖酐预防HSCT后HVOD安全有效。

Salvia miltiorrhiza combined with dextran to prevent veno-occlusive disease after hematopoietic stem cell transplantation

Objective To investigate the clinic effect of the Salvia miltiorrhiza combined with dextran to prevent veno-occlusive disease after hematopoietic stem cell transplantation. Methods In the process of the pretreatment of the hematopoietic stem cell transplantation, patients were treated with salvia miltiorrhiza (20 ml/d), dextran(250 ml, twice a day) by venous transfusion and the drugs to protect the liver cell was used in the same time. When the count of platelet dropped to 30×109/L, salvia miltiorrhiza and dextranware stopped applying forever. Results Veno-occlusive disease and hemorrhage has not occurred during 85 times of the hematopoietic stem cell transplantation treated with salvia miltiorrhiza and dextran. Conclusion We conclude that the combined treatment with salvia miltiorrhiza and dextran is safe and effective to prevent veno-occlusive disease after hematopoietic stem cell transplantation.